Silence Therapeutics and AstraZeneca extend siRNA development collaboration

UK biotechnology firm Silence Therapeutics has announced a one-year extension of its ongoing research and development collaboration with Anglo-Swedish drug major AstraZeneca. Under the terms of the agreement, which has progressed well since being signed in July 2007, Silence and AstraZeneca are jointly collaborating in the identification and optimization of five novel siRNA therapeutic molecules addressing respiratory and oncology indications.

Under the terms of the accord, AstraZeneca will retain full responsibility for clinical development and commercialization of the siRNA molecules. As announced previously, in addition to the initial £7.5 million ($11.3 million) access fee paid to Silence in July 2007, the collaboration may generate up to £200 million in fees and milestone payments plus royalties on product sales. The terms of this collaboration deal are independent of Silence's siRNA delivery collaboration with AstraZeneca which was also extended in April this year.

Commenting on today's announcement, Philip Haworth, chief executive of Silence, said: "The extension of our development collaboration with AstraZeneca is testament to the successful relationship and the progress made in this collaboration. Both teams are working closely together to optimize the five therapeutic programs based on Silence's leading siRNA technology, in addition to our collaboration investigating new delivery approaches for RNA interference. AstraZeneca is a strong endorsement of our technology and we are delighted to continue working together."